Tag: GlobeNewswire

Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond

ZUG, Switzerland, October 29^th, 2026 — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced upcoming presentations highlighting Privosegtor’s neuroprotective potential and its ongoing development in optic neuritis at the 6th Asia-Pacific Ophthalmic Innovation Society Congress and the CNS Summit.

Oculis will sponsor the 6^th Asia-Pacific Ophthalmic Innovation Society Congress, where Riad Sherif, M.D., Chief Executive Officer, will present an overview of Privosegtor and the PIONEER registrational program.

Privosegtor is a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers and could become the first neuroprotective therapy for optic neuritis. It is currently being evaluated in PIONEER-1, a registrational trial enrolling patients with acute-onset optic neuritis, including patients with and without multiple sclerosis.

Aaron Tansy, M.D., Vice President, Development Franchise Head, Neurology at Oculis, on behalf of the authors, will present Phase 2 ACUITY data at the CNS Summit on November 2^nd and 3^rd. The ACUITY trial evaluated Privosegtor in patients with acute optic neuritis and showed improvements in visual function, supported by anatomical preservation of the retina and reductions in blood neurofilament levels.

The positive ACUITY findings supported the granting of Breakthrough Therapy designation by the U.S. Food and Drug Administration and PRIority Medicines (PRIME) designation by the European Medicines Agency for Privosegtor in optic neuritis. Oculis is advancing Privosegtor through the PIONEER registrational program in optic neuropathies and, building on the ACUITY dataset and constructive pre-IND feedback from the FDA’s Neurology division, is also anticipating clearance of an IND for the treatment of acute multiple sclerosis relapses in Q4 2026.

Details of Oculis’ presentations are as follows:

6^th Asia-Pacific Ophthalmic Innovation Society (APOIS) 2026 Congress, October 30^th  – November 1^st :

• Session: Next Waves Technologies II

Presenter:  Riad Sherif, M.D., Chief Executive Officer at Oculis
Date/Time: November 1^st, 2026; 10:30 AM -12:30 PM KST
Location: Grand Walkerhill, Seoul, South Korea

CNS Summit, November 1^st to 4^th:

• Abstract title: Improved Low Contrast Visual Acuity, Reduction in Retinal Ganglion Cell Loss, and Neurofilaments-light with Privosegtor in Acute Optic Neuritis: Results from a Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial

Presenter: Aaron Tansy, M.D., Vice President, Development Franchise Head, Neurology at Oculis, on behalf of authors
Date/Time: November 2^nd and 3^rd, from 5:00 to 7:00 PM EDT
Location: Encore Boston Harbor, Everett, MA, USA

– Ends –

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis and non-arteritic anterior ischemic optic neuropathy. Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; and the timing or likelihood of regulatory filings and approvals, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond

ZUG, Switzerland, October 29^th, 2026 — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced upcoming presentations highlighting Privosegtor’s neuroprotective potential and its ongoing development in optic neuritis at the 6th Asia-Pacific Ophthalmic Innovation Society Congress and the CNS Summit.

Oculis will sponsor the 6^th Asia-Pacific Ophthalmic Innovation Society Congress, where Riad Sherif, M.D., Chief Executive Officer, will present an overview of Privosegtor and the PIONEER registrational program.

Privosegtor is a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers and could become the first neuroprotective therapy for optic neuritis. It is currently being evaluated in PIONEER-1, a registrational trial enrolling patients with acute-onset optic neuritis, including patients with and without multiple sclerosis.

Aaron Tansy, M.D., Vice President, Development Franchise Head, Neurology at Oculis, on behalf of the authors, will present Phase 2 ACUITY data at the CNS Summit on November 2^nd and 3^rd. The ACUITY trial evaluated Privosegtor in patients with acute optic neuritis and showed improvements in visual function, supported by anatomical preservation of the retina and reductions in blood neurofilament levels.

The positive ACUITY findings supported the granting of Breakthrough Therapy designation by the U.S. Food and Drug Administration and PRIority Medicines (PRIME) designation by the European Medicines Agency for Privosegtor in optic neuritis. Oculis is advancing Privosegtor through the PIONEER registrational program in optic neuropathies and, building on the ACUITY dataset and constructive pre-IND feedback from the FDA’s Neurology division, is also anticipating clearance of an IND for the treatment of acute multiple sclerosis relapses in Q4 2026.

Details of Oculis’ presentations are as follows:

6^th Asia-Pacific Ophthalmic Innovation Society (APOIS) 2026 Congress, October 30^th  – November 1^st :

• Session: Next Waves Technologies II

Presenter:  Riad Sherif, M.D., Chief Executive Officer at Oculis
Date/Time: November 1^st, 2026; 10:30 AM -12:30 PM KST
Location: Grand Walkerhill, Seoul, South Korea

CNS Summit, November 1^st to 4^th:

• Abstract title: Improved Low Contrast Visual Acuity, Reduction in Retinal Ganglion Cell Loss, and Neurofilaments-light with Privosegtor in Acute Optic Neuritis: Results from a Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial

Presenter: Aaron Tansy, M.D., Vice President, Development Franchise Head, Neurology at Oculis, on behalf of authors
Date/Time: November 2^nd and 3^rd, from 5:00 to 7:00 PM EDT
Location: Encore Boston Harbor, Everett, MA, USA

– Ends –

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis and non-arteritic anterior ischemic optic neuropathy. Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; and the timing or likelihood of regulatory filings and approvals, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

October 29, 2026

New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make informed decisions during treatment.

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and a pioneer in image-guided therapy, today announced the launch of Philips UniGuide 3D Live Guidance in Europe and other CE-marked markets.

Interventional care increasingly depends on combining information from multiple imaging sources. Philips is advancing its vision of a more connected interventional ecosystem. UniGuide represents the next step in that journey by enabling physicians to access relevant planning information within the same workflow they use to guide treatment. Built on the foundation of the Philips Azurion platform, a widely adopted image-guided therapy system known for its workflow efficiency and user experience, UniGuide helps physicians bring pre-procedural planning insights directly into the live procedure, allowing physicians to access planning information where treatment decisions are made.

The first release of UniGuide connects preprocedural CT insights to the live Azurion workflow, supporting more informed, patient-specific treatment decisions in PCI, structural heart and complex vascular procedures.

Built on the strength of Azurion
For more than a decade, Philips has been at the forefront of innovation in interventional cardiology. Its industry-leading Azurion platform has helped cath labs worldwide simplify workflows, improve staff efficiency and support better patient care by combining advanced imaging, intuitive user interaction and seamless workflow integration.

The next frontier is making better use of the wealth of information available before treatment even begins.

Bringing insights from CT scans into the procedure
CT imaging provides detailed 3D insights before an intervention, helping physicians assess vessel characteristics, understand disease presentation, and plan treatment strategies. However, those insights are often reviewed separately from the systems used during the procedure, requiring physicians to switch between platforms and mentally correlate planning information with live image guidance.

Integrated directly into the Azurion environment, UniGuide is designed to address this challenge by making relevant CT-derived information available within the workflow physicians already use every day.

For coronary interventions (CT-guided PCI), insights derived from a coronary CT angiography (CCTA) scan performed before PCI can be combined with live image guidance through 3D overlay visualization or synchronized side-by-side display. This enables physicians to access vessel information and additional CT-derived insights, including plaque characteristics and other disease-related information, during the procedure.

“Bringing CT into the cathlab creates a huge opportunity for those patients who have already undergone CT imaging,” said Prof. Javier Escaned, MD, PhD, Head of the Interventional Cardiology Section, Hospital Clínico San Carlos and Complutense University, Madrid. “Access to the CT angiogram allows us to assess relevant aspects of the vessels we are going to treat, improve procedural planning, and improve the precision of the intervention. We can also review specific aspects of the CT inside the cathlab using the table-side touchscreen (TSM) and synchronize the movement of the 3D CT rendering with the C-arm. Together, these capabilities contribute to better guidance and higher precision of the interventions.

Open ecosystem for Philips and compatible third-party planning sources
UniGuide supports an open planning ecosystem, allowing healthcare providers to use planning insights from Philips Advanced Visualization Workspace and compatible third-party solutions within the live Azurion workflow [1]. This flexibility helps protect existing investments while giving healthcare providers greater choice in how they plan and guide interventions.

Designed for usability and workflow efficiency
UniGuide is fully integrated into the Azurion workflow, allowing physicians to access CT and planning information on the large FlexVision display and interact with 3D guidance through the tableside Touch Screen Module. By minimizing the need to move between systems and workstations, UniGuide helps keep the focus on the patient and procedure.

In a Philips usability study, 93% of participating clinicians believed that bringing planning information directly into the procedural workflow could help improve cath lab efficiency and performance, while 80% indicated that UniGuide’s automation and intuitive user experience could help physicians maintain focus during procedures. [2]

“We are increasingly able to understand a patient’s anatomy and plan complex procedures well before the patient enters the interventional suite. With UniGuide, we’re putting that knowledge to work during treatment, connecting CT planning with live guidance to help physicians make more informed, patient-specific decisions,” said Darshan Doshi, Interventional Cardiologist and Chief Medical Officer for Image Guided Therapy Devices at Philips.

A foundation for the future of image-guided therapy
UniGuide marks Philips’ broader strategy to build on the capabilities of the Azurion platform and create a more connected environment for image-guided therapy. By bringing planning, diagnostic, and procedural information together within a single workflow, Philips aims to support clinical decision-making during complex interventions while enabling access to increasingly comprehensive clinical information.

Over time, Philips intends to expand this foundation across multiple imaging modalities, clinical applications, and procedure types, making relevant information available when and where treatment decisions are made.

Philips UniGuide 3D Live Guidance is CE marked and is available for sale in CE-marked markets from October 23, 2026. UniGuide 3D Live Guidance is currently not available for sale in the United States.

[1] The preprocedural planning solution should meet the DICOM conformance statement issued by Philips.
[2] Results obtained during a Philips claims substantiation study performed in March 2026. Responses are based on 15 clinicians from the United States who completed a questionnaire following a usability study and additional hands-on time with Philips Azurion and UniGuide.

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips 

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Physicians using Philips UniGuide
• Philips UniGuide showing preprocedural CT insights
• Philips Azurion image-guided therapy platform with UniGuide

October 29, 2026

New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make informed decisions during treatment.

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and a pioneer in image-guided therapy, today announced the launch of Philips UniGuide 3D Live Guidance in Europe and other CE-marked markets.

Interventional care increasingly depends on combining information from multiple imaging sources. Philips is advancing its vision of a more connected interventional ecosystem. UniGuide represents the next step in that journey by enabling physicians to access relevant planning information within the same workflow they use to guide treatment. Built on the foundation of the Philips Azurion platform, a widely adopted image-guided therapy system known for its workflow efficiency and user experience, UniGuide helps physicians bring pre-procedural planning insights directly into the live procedure, allowing physicians to access planning information where treatment decisions are made.

The first release of UniGuide connects preprocedural CT insights to the live Azurion workflow, supporting more informed, patient-specific treatment decisions in PCI, structural heart and complex vascular procedures.

Built on the strength of Azurion
For more than a decade, Philips has been at the forefront of innovation in interventional cardiology. Its industry-leading Azurion platform has helped cath labs worldwide simplify workflows, improve staff efficiency and support better patient care by combining advanced imaging, intuitive user interaction and seamless workflow integration.

The next frontier is making better use of the wealth of information available before treatment even begins.

Bringing insights from CT scans into the procedure
CT imaging provides detailed 3D insights before an intervention, helping physicians assess vessel characteristics, understand disease presentation, and plan treatment strategies. However, those insights are often reviewed separately from the systems used during the procedure, requiring physicians to switch between platforms and mentally correlate planning information with live image guidance.

Integrated directly into the Azurion environment, UniGuide is designed to address this challenge by making relevant CT-derived information available within the workflow physicians already use every day.

For coronary interventions (CT-guided PCI), insights derived from a coronary CT angiography (CCTA) scan performed before PCI can be combined with live image guidance through 3D overlay visualization or synchronized side-by-side display. This enables physicians to access vessel information and additional CT-derived insights, including plaque characteristics and other disease-related information, during the procedure.

“Bringing CT into the cathlab creates a huge opportunity for those patients who have already undergone CT imaging,” said Prof. Javier Escaned, MD, PhD, Head of the Interventional Cardiology Section, Hospital Clínico San Carlos and Complutense University, Madrid. “Access to the CT angiogram allows us to assess relevant aspects of the vessels we are going to treat, improve procedural planning, and improve the precision of the intervention. We can also review specific aspects of the CT inside the cathlab using the table-side touchscreen (TSM) and synchronize the movement of the 3D CT rendering with the C-arm. Together, these capabilities contribute to better guidance and higher precision of the interventions.

Open ecosystem for Philips and compatible third-party planning sources
UniGuide supports an open planning ecosystem, allowing healthcare providers to use planning insights from Philips Advanced Visualization Workspace and compatible third-party solutions within the live Azurion workflow [1]. This flexibility helps protect existing investments while giving healthcare providers greater choice in how they plan and guide interventions.

Designed for usability and workflow efficiency
UniGuide is fully integrated into the Azurion workflow, allowing physicians to access CT and planning information on the large FlexVision display and interact with 3D guidance through the tableside Touch Screen Module. By minimizing the need to move between systems and workstations, UniGuide helps keep the focus on the patient and procedure.

In a Philips usability study, 93% of participating clinicians believed that bringing planning information directly into the procedural workflow could help improve cath lab efficiency and performance, while 80% indicated that UniGuide’s automation and intuitive user experience could help physicians maintain focus during procedures. [2]

“We are increasingly able to understand a patient’s anatomy and plan complex procedures well before the patient enters the interventional suite. With UniGuide, we’re putting that knowledge to work during treatment, connecting CT planning with live guidance to help physicians make more informed, patient-specific decisions,” said Darshan Doshi, Interventional Cardiologist and Chief Medical Officer for Image Guided Therapy Devices at Philips.

A foundation for the future of image-guided therapy
UniGuide marks Philips’ broader strategy to build on the capabilities of the Azurion platform and create a more connected environment for image-guided therapy. By bringing planning, diagnostic, and procedural information together within a single workflow, Philips aims to support clinical decision-making during complex interventions while enabling access to increasingly comprehensive clinical information.

Over time, Philips intends to expand this foundation across multiple imaging modalities, clinical applications, and procedure types, making relevant information available when and where treatment decisions are made.

Philips UniGuide 3D Live Guidance is CE marked and is available for sale in CE-marked markets from October 23, 2026. UniGuide 3D Live Guidance is currently not available for sale in the United States.

[1] The preprocedural planning solution should meet the DICOM conformance statement issued by Philips.
[2] Results obtained during a Philips claims substantiation study performed in March 2026. Responses are based on 15 clinicians from the United States who completed a questionnaire following a usability study and additional hands-on time with Philips Azurion and UniGuide.

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips 

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Physicians using Philips UniGuide
• Philips UniGuide showing preprocedural CT insights
• Philips Azurion image-guided therapy platform with UniGuide

Alphen aan den Rijn – October 29, 2026 – Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 479 of its own ordinary shares in the period from October 22, 2026, up to and including October 28, 2026, for €0.04 million and at an average share price of €85.98.

These repurchases are part of the share buyback program announced on February 25, 2026, under which we intend to repurchase shares for up to €500 million during 2026.

The cumulative amounts repurchased in the year to date under this program are as follows:

Share Buyback 2026

Period	Cumulative shares repurchased in period	Total consideration (€ million)	Average share price (€)
2026 to date	3,888,001	264.2	67.96

For the period starting August 6, 2026, up to and including December 28, 2026, we have engaged a third party to execute €256 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association.

Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation.

Further information is available on our website:

• Download the share buyback transactions excel sheet for detailed individual transaction information.
• Weekly reports on the progress of our share repurchases.
• Overview of share buyback programs.

For more information about Wolters Kluwer, please visit: www.wolterskluwer.com.

###

About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2025 annual revenues of €6.1 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,100 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). 

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

Media	Investors/Analysts
Marnie Kontovraki	Meg Geldens
Director	Vice President
Global Communications	Investor Relations
press@wolterskluwer.com	ir@wolterskluwer.com

Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries.

Attachment

• 20261029 Share Buyback Transactions Oct_22_Oct 28_2026

Alphen aan den Rijn – October 29, 2026 – Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 479 of its own ordinary shares in the period from October 22, 2026, up to and including October 28, 2026, for €0.04 million and at an average share price of €85.98.

These repurchases are part of the share buyback program announced on February 25, 2026, under which we intend to repurchase shares for up to €500 million during 2026.

The cumulative amounts repurchased in the year to date under this program are as follows:

Share Buyback 2026

Period	Cumulative shares repurchased in period	Total consideration (€ million)	Average share price (€)
2026 to date	3,888,001	264.2	67.96

For the period starting August 6, 2026, up to and including December 28, 2026, we have engaged a third party to execute €256 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association.

Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation.

Further information is available on our website:

• Download the share buyback transactions excel sheet for detailed individual transaction information.
• Weekly reports on the progress of our share repurchases.
• Overview of share buyback programs.

For more information about Wolters Kluwer, please visit: www.wolterskluwer.com.

###

About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2025 annual revenues of €6.1 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,100 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). 

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

Media	Investors/Analysts
Marnie Kontovraki	Meg Geldens
Director	Vice President
Global Communications	Investor Relations
press@wolterskluwer.com	ir@wolterskluwer.com

Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries.

Attachment

• 20261029 Share Buyback Transactions Oct_22_Oct 28_2026

The Board of Director of Tivoli A/S has adopted the interim report for the period 1 January – 30 September 2026 on 29 October 2026.  
 
Results for the period 1 January – 30 September 2026 in outline:   

• A revenue of DKK of 937.9 million compared to DKK 886.5 million last year (6%).
• An EBITDA of DKK 108.6 million compared to DKK 123.2 million last year (-12%).
• A profit before tax of DKK 13.3 million compared to DKK 34.6 million last year (-62%).
• 2,682 thousand visitors compared to 2,689 last year (-0.3%). 

The increased activity level, the opening of Hikari and several strategic initiatives have increased the cost level compared to last year. The profit before tax for the first nine months was thus lower than in the same period last year.

”Tivoli delivered a third quarter, with growth in both revenue and earnings. A very well-attended Halloween season underlines the positive development of the business. With the opening of the new Hikari attraction area, Tivoli also took a major and important step in the long-term development of the Tivoli Gardens. Hikari is off to a good start and is already making a positive contribution to the business. At the same time, the area demonstrates how we can continue to develop Tivoli and create new experiences while respecting what our guests already appreciate. This provides us with a solid foundation for the remainder of the year, and from 13 November, we look forward to welcoming guests to Christmas in Tivoli. On this basis, we maintain our expectations for 2026.”, says CEO, Susanne Mørch Koch.
 
Outlook for 2026 (unchanged) 
Tivoli is thus well prepared for the last season of the year, when Christmas in Tivoli opens on 13 November and this year lasts until 3 January 2027. Against this background, Tivoli maintains its expectations for 2026 with revenue of around DKK 1,400 million and a profit before tax of DKK 145 million.

Best regards 

Tom Knutzen                        Susanne Mørch Koch 
Chairman                            CEO 

 
Contact person: head of Press, Torben Plank phone 22237440 / tpl@tivoli.dk

Attachments

• Tivoli AS – Stock Exchange Announcement no 8 – Interim Report for the period 1 January – 30 September 2026
• Tivoli AS – Interim report Q3 26

Festi hf. published its Q3 2026 results after market close on 28 October 2026.

Attached is the Q3 2026 investor presentation, which will be presented at today’s results meeting for market participants, Thursday 29 October 2026, at 8:30.

Attachment

• Festi hf. – Presentation of Q3 2026 Results

International Petroleum Corporation (IPC) (TSX, Nasdaq Stockholm: IPCO) will publish its financial and operating results and related management’s discussion and analysis for the three and nine months ended September 30, 2026, on Tuesday, November 3, 2026 at 07:30 CET, followed by an audiocast at 09:00 CET

TORONTO, Oct. 29, 2026 (GLOBE NEWSWIRE) — Listen to William Lundin, President and CEO, and Christophe Nerguararian, CFO, commenting on the third quarter 2026 financial and operating results and the latest developments from IPC.

Follow the presentation live starting at 09:00 CET on Tuesday, November 3, 2026 on www.international-petroleum.com or using the link or dial-in details below:

Presentation Link: https://ipc.videosync.fi/2026-11-03

	Dial-in numbers	Canada/USA:	+1 786 697 3501
		UK:	+44 33 0551 0200
		Sweden:	+46 8 5052 0424
	Password	Quote “IPC” when prompted by the operator

International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm under the symbol “IPCO”. 

For further information, please contact:

	Rebecca Gordon		Robert Eriksson
	SVP Corporate Planning and Investor Relations		Media Manager
	rebecca.gordon@international-petroleum.com	Or	reriksson@rive6.ch
	Tel: +41 22 595 10 50		Tel: +46 701 11 26 15

Forward-Looking Statements
This press release contains statements and information which constitute “forward-looking statements” or “forward-looking information” (within the meaning of applicable securities legislation). Such statements and information (together, “forward-looking statements”) relate to future events, including the Corporation’s future performance, business prospects or opportunities. Actual results may differ materially from those expressed or implied by forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Forward-looking statements speak only as of the date of this press release, unless otherwise indicated. IPC does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws.

All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, forecasts, guidance, budgets, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “forecast”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “budget” and similar expressions) are not statements of historical fact and may be “forward-looking statements”.

International Petroleum Corporation (IPC) (TSX, Nasdaq Stockholm: IPCO) will publish its financial and operating results and related management’s discussion and analysis for the three and nine months ended September 30, 2026, on Tuesday, November 3, 2026 at 07:30 CET, followed by an audiocast at 09:00 CET.

Listen to William Lundin, President and CEO, and Christophe Nerguararian, CFO, commenting on the third quarter 2026 financial and operating results and the latest developments from IPC.

Follow the presentation live starting at 09:00 CET on Tuesday, November 3, 2026 on www.international-petroleum.com or using the link or dial-in details below:

Presentation Link: https://ipc.videosync.fi/2026-11-03

Dial-in numbers	Canada/USA:	+1 786 697 3501
	UK:	+44 33 0551 0200
	Sweden:	+46 8 5052 0424
Password	Quote “IPC” when prompted by the operator

 

International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm under the symbol “IPCO”.

For further information, please contact:

Rebecca Gordon SVP Corporate Planning and Investor Relations rebecca.gordon@international-petroleum.com Tel: +41 22 595 10 50

Or

Robert Eriksson Media Manager reriksson@rive6.ch Tel: +46 701 11 26 15

 

Forward-Looking Statements
This press release contains statements and information which constitute “forward-looking statements” or “forward-looking information” (within the meaning of applicable securities legislation). Such statements and information (together, “forward-looking statements”) relate to future events, including the Corporation’s future performance, business prospects or opportunities. Actual results may differ materially from those expressed or implied by forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Forward-looking statements speak only as of the date of this press release, unless otherwise indicated. IPC does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws.

All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, forecasts, guidance, budgets, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “forecast”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “budget” and similar expressions) are not statements of historical fact and may be “forward-looking statements”.

Attachment

• IPC PR Q3 2026 release advance 29-10-2026